FabRx Directors awarded €5 million to develop better medicines

May 20, 2020 | Featured

FabRx’s Directors, Professor Abdul Basit and Professor Simon Gaisford, and partners have successfully been awarded a grant totalling over €5 million within the Interreg 2 Seas programme. UCL School of Pharmacy, in collaboration with the Universities of Cambridge, Delft, Ghent, Leiden and Lille, will lead a project which aims to improve oral drug delivery, involving the use of 3D printing for advanced medicine development.

Interreg 2 Seas logo with map showing the participating countries

Success from this project will contribute towards optimising drug therapy and reducing cost burdens from hospitalisations following adverse drug effects which is estimated at €79 billion per year in Europe. The critical mass needed to unite the level of knowhow, facilities, theoretical and experimental techniques is only reached by the cross-border collaboration of world-wide leading specialists.

Professor Basit shares, “We are delighted to work alongside the whole European consortium under the Interreg 2 Seas Programme and strive to improve current treatments strategies for the benefit of patients using innovative technologies, such as 3D printing.”

Back to News

Copyright © 2018 FabRx Ltd